ArticleBioengineering (Basel, Switzerland)2025
Extracorporal Ovary Bioreactor System with Oxygen Supply and Drug Delivery Option.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Young women who have survived cancer may have lost their fertility due to cytotoxic treatments like chemotherapy or irradiation. So far, oocyte or ovarian tissue cryopreservation are well-known and well-used opportunities for fertility preservation prior cytotoxic therapies. However, these methods are not possible in certain cases, like those with a high risk of ovarian metastasis or prepubertal girls. Therefore, new medical and biotechnological options are also being sought to help this patient group to fulfill their desire to have their own biological children. The investigation described here focuses on the possibility of in vitro follicle maturing. To this point, a long-term temperature and pH-controlled bioreactor system is developed that can supply a whole ovary with oxygen and nutrients over several days and offers the possibility of hormone administration or the delivery of other drugs. This bioreactor was then tested with mature bovine ovaries. After appropriate cannulation, antithrombotic vascular perfusion, and antibiotic pretreatment, the ovaries were cultured for up to 9 days without any contamination or suffering major vital cell damage. The controlled application of oocyte stimulation hormones (human menopausal gonadotropin; hMG) also enabled successful in vitro follicle growth and maturation. From a technical point of view, there is still optimization potential for this bioreactor system, but in principle, it has been demonstrated that long-term ovary cultivation and in vitro maturation of follicles are possible, which opens up further potential for these and other applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.